ALLERGY THERAPEUTICS (UK) LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +3.3%

  £24,564,000 → £25,366,000

• Cash

  +33.5%

  £8,419,000 → £11,243,000

• Net assets

  -21.2%

  -£171,825,000 → -£208,279,000

• Employees

  +2.2%

  314 → 321

• Operating profit

  +19%

  -£35,834,000 → -£29,032,000

• Profit before tax

  +8.3%

  -£39,810,000 → -£36,515,000

• Wages

  +1.4%

  £15,143,000 → £15,352,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. ALLERGY THERAPEUTICS (UK) LIMITED 2004-09-24 → present
2. ALLERGY THERAPEUTICS LTD 1998-03-26 → 2004-09-24
3. HAMSUDD TWO THOUSAND AND ONE LIMITED 1998-01-07 → 1998-03-26

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Financial Statements have been prepared on a going concern basis after considering the Group's and the Company's current cash position and reviewing budgets and cash flow forecasts for a period of at least twelve months from the date of approval of these Financial Statements.”

Significant events

• “Proceeds from Exercise of Warrants and Repayment of the Entire Balance under the Shareholder Facility”
• “Renewed Shareholder Facility”
• “Exploration of listing in Hong Kong”
• “Marketing authorisation for Grass MATA MPL (Grassmuno®) On 16 December 2025, Allergy Therapeutics plc received marketing authorisation from the Paul Ehrlich Institut (PEI) in Germany for its subcutaneous grass pollen allergen immunotherapy, Grass MATA MPL, to be commercialised under the brand name Grassmuno®.”
• “Hayfin Facilities, Warrant Exercise and Subscription On 20 February 2026, the Group entered into an amendment to the secured senior loan facility, entered into in October 2024 (the "2024 Hayfin Facility") with Hayfin Healthcare Opportunities LuxCo S.a.r.l., a fund advised by Hayfin Capital Management LLP ("Hayfin"), under which a new £40m senior secured facility (the "2026 Hayfin Facility) was made available to the Group.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.